Business
Genmab Announces Financial Results for the Nine Months of 2025
November 6, 2025 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2025 Highlights Announcement of Genmab’s proposed acquisition of Merus N.V. (Merus)Genmab revenue increased 21% compared to the first nine months of 2024, to $2,662 millionFDA granted BTD to Rina-S® in advanced endometrial cancerEpcoritamab Phase 3 EPCORE® FL-1 trial met dual primary endpoints of ORR and PFS, demonstrating statistically significant and clinically meaningful differences in both endpointsF
About this update from Genmab A/s
[{"type":"image","alt":"Genmab A/S","displaySize":"","headline":null,"caption":"Genmab A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":275,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3fXMaEmkURmdIw8oGLJV.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d","width":275,"height":85}},"lazy":false},{"type":"text","content":"November 6, 2025 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2025","length":98,"tagName":"p"},{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announcement of Genmab’s proposed acquisition of Merus N.V. (Merus)","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Genmab revenue increased 21% compared to the first nine months of 2024, to $2,662 million","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA granted BTD to Rina-S® in advanced endometrial cancer","length":57,"tagName":"p"}]},{"val":[{"type":"text","content":"Epcoritamab Phase 3 EPCORE® FL-1 trial met dual primary endpoints of ORR and PFS, demonstrating statistically significant and clinically meaningful differences in both endpoints","length":177,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA granted priority review of the sBLA for epcoritamab plus R2 in patients with relapsed or refractory FL","length":106,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":496,"olType":false},{"type":"text","content":"“In the third quarter we made advances that underscore the potential of our late-stage portfolio; Epcoritamab moved closer to being available to patients in earlier lines of therapy for follicular lymphoma and Rina-S was granted Breakthrough Therapy Designation (BTD) in advanced endometrial cancer. With robust development plans for both epcoritamab and Rina-S and with Tivdak® (tisotumab vedotin) now available for prescribing in Germany - our first commercial entry into a European market - we continue to execute on our strategic imperatives to accelerate our late-stage pipeline and maximize our approved medicines to reach more patients,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “In addition, our pr...